The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that strengthens the position of global pharmaceutical firms in Asia's growing oncology sector, AstraZeneca and Abbisko have announced a collaboration to develop a combination therapy for non-small cell lung cancer (NSCLC). This partnership follows the Investigational New Drug (IND) clearance in China to commence Phase 1/2 clinical trials. The research will specifically focus on combining lumipodlin with AstraZeneca’s established drug, Tagrisso.
This expansion in China reflects AstraZeneca's strategy to bolster its cancer treatment portfolio, as Tagrisso sales have shown significant growth in emerging markets in recent quarters according to prior earnings reports. The company competes in this space with giants such as Roche and Merck, who are also expanding clinical trial footprints in the region. Per market data, the Chinese healthcare sector is seeing an influx of investment in innovative therapies to offset traditional pricing pressures.
Sign in to access this content
Sign InAZN stock stood at $195.665 (at close July 02, 2026), having reached an intraday high of $196.425. Investors are looking ahead to China's Manufacturing PMI data scheduled for June 30, which may provide signals regarding the broader business environment. Traders will also monitor additional clinical updates that could impact the stock's support and resistance levels in the near term.